Journal of Cancer Metastasis and Treatment最新文献_第4页

Recent advances in detecting premalignant pancreatic cysts 恶性前胰腺囊肿的检测新进展

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.122

M. Jalal, Sebastine A. Gbadegesin, Sazgar Ibrahim, N. Tehami

引用次数: 0

Management of oligometastatic disease in soft tissue sarcomas 软组织肉瘤少转移性疾病的治疗

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.132

Marcos R. Gonzalez

{"title":"Management of oligometastatic disease in soft tissue sarcomas","authors":"Marcos R. Gonzalez","doi":"10.20517/2394-4722.2022.132","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.132","url":null,"abstract":"Oligometastatic soft tissue sarcoma represents an intermediate state between localized and disseminated disease. Combination A combination of surgery, radiotherapy and systemic treatment significantly improves prognosis, with a 5-year overall survival as high as 50%. Due to the high prevalence of lung metastases, most of the surgical evidence is centered around lung metastasectomy. The decision to perform surgical metastasectomy remains dependent on optimal patient selection. Adequate post-surgical lung function, absence of extrapulmonary metastases, control of the primary tumor, and feasibility of achieving negative margins are major criteria for patients to undergo successful surgery. Adequate margins, longer disease-free interval, unilateral, limited number (≤ 2), metachronous and small (< 2 cm) pulmonary metastasis are some factors associated with improved survival. Radiotherapy, especially SBRT, is an effective treatment for disease control, and its use as (neo)-adjuvant therapy has shown promising results. However, studies comparing radiotherapy against surgery are missing and the efficacy of radiotherapy independent of surgery is not yet clear. Interventional radiology techniques such as percutaneous thermal ablation (PTA) or arterial embolization have also been described as potential treatment alternatives in candidates deemed not fit for surgery. Systemic treatment has traditionally consisted of an anthracycline (doxorubicin)-based regimen with the addition of ifosfamide in certain cases. Recent advances in systemic treatment include the use of targeted therapy and immunotherapy in (oligo)-metastatic STS. However, except for certain histologies, most STS subtypes are chemoresistant, and the response to systemic treatment is poor.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical resistance predictors to first-line VEGFR-TKI monotherapy for metastatic renal cell carcinoma: a retrospective multicenter real-life case series 转移性肾细胞癌一线VEGFR-TKI单药治疗的临床耐药预测因素:回顾性多中心真实病例系列

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2023.41

Pezzicoli Gaetano, Quaglini Silvana, Tibollo Valentina, Bersanelli Melissa, Porta Camillo, Rizzo Mimma

{"title":"Clinical resistance predictors to first-line VEGFR-TKI monotherapy for metastatic renal cell carcinoma: a retrospective multicenter real-life case series","authors":"Pezzicoli Gaetano, Quaglini Silvana, Tibollo Valentina, Bersanelli Melissa, Porta Camillo, Rizzo Mimma","doi":"10.20517/2394-4722.2023.41","DOIUrl":"https://doi.org/10.20517/2394-4722.2023.41","url":null,"abstract":"Aim: For many years, systemic treatment of metastatic Renal Cell Carcinoma (mRCC) was based on sequential targeted agent monotherapies. In this real-life case series, we evaluated easily accessible clinical factors useful for disease course prediction. Methods: We exploited patients' clinical pathological characteristics and systemic treatment outcomes in a real-world population of 365 mRCC patients who received sequential monotherapies in the targeted therapy era, and we identified an early progressors subpopulation, resistant to first-line VEGFR-TKI monotherapy in less than 6 months. Results: Early progressors (n = 124) show a far worse OS compared with patients progressing beyond the sixthmonth of therapy (13.5 vs. 44.8 months, P-value < 0.0001, HR = 0.41, 95%CI: 0.29-0.53). However, these patients did not show far worse performance in second and third-line settings compared to first-line responders. In the univariate analysis, IMDC risk class, sarcomatoid features, and Systemic Inflammation Index (SII) were correlated with first-line therapy Progression-Free Survival (PFS1). In multivariate analysis, variables correlated with first-line outcome were IMDC risk class, histotype, and number of metastatic sites at the diagnosis. Conclusion: Real-world data can contribute to developing easy-to-use prognostic factors associated with refractory disease that could support clinicians in identifying the most appropriate treatment strategy for each patient.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136054151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chemoprevention of neuroblastoma: progress and promise beyond uncertainties. 神经母细胞瘤的化学预防：不确定因素之外的进展与希望。

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-03-31 DOI: 10.20517/2394-4722.2022.40

Natarajan Aravindan, Mohan Natarajan, Dinesh Babu Somasundaram, Sheeja Aravindan

{"title":"Chemoprevention of neuroblastoma: progress and promise beyond uncertainties.","authors":"Natarajan Aravindan, Mohan Natarajan, Dinesh Babu Somasundaram, Sheeja Aravindan","doi":"10.20517/2394-4722.2022.40","DOIUrl":"10.20517/2394-4722.2022.40","url":null,"abstract":"Neuroblastoma is the most common extracranial solid tumor in children and comprises one-tenth of all childhood cancer deaths. The current clinical therapy for this deadly disease is multimodal, involving an induction phase with alternating regimens of high-dose chemotherapeutic drugs and load reduction surgery; a consolidation phase with more intensive chemotherapy, radiotherapy, and stem cell transplant; and a maintenance phase with immunotherapy and immune-activating cytokine treatment. Despite such intensive treatment, children with neuroblastoma have unacceptable life quality and survival, warranting preventive measures to regulate the cellular functions that orchestrate tumor progression, therapy resistance, metastasis, and tumor relapse/recurrence. Globally, active efforts are underway to identify novel chemopreventive agents, define their mechanism(s) of action, and assess their clinical benefit. Some chemoprevention strategies (e.g., retinoids, difluoromethylornithine) have already been adopted clinically as part of maintenance phase therapy. Several agents are in the pipeline, while many others are in preclinical characterization. Here we review the classes of chemopreventive agents investigated for neuroblastoma, including cellular events targeted, mode(s) of action, and the level of development. Our review: (i) highlights the pressing need for new and improved chemopreventive strategies for progressive neuroblastoma; (ii) lists the emerging classes of chemopreventive agents for neuroblastoma; and (iii) recognizes the relevance of targeting dynamically evolving hallmark functions of tumor evolution (e.g., survival, differentiation, lineage transformation). With recent gains in the understanding of tumor evolution processes and preclinical and clinical efforts, it is our strong opinion that effective chemopreventive strategies for aggressive neuroblastoma are a near reality.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into the co-evolution of glioblastoma and associated macrophages 胶质母细胞瘤和相关巨噬细胞的共同进化

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2023.09

David Eisenbarth, Y. A. Wang

{"title":"Insights into the co-evolution of glioblastoma and associated macrophages","authors":"David Eisenbarth, Y. A. Wang","doi":"10.20517/2394-4722.2023.09","DOIUrl":"https://doi.org/10.20517/2394-4722.2023.09","url":null,"abstract":"Glioblastoma (GBM) is one of the most immunosuppressive and heterogeneous tumors with limited treatment options. Most studies relied on treatment-experienced patient samples to elucidate the origins of tumor heterogeneity, introducing bias into the analysis. The analysis of samples from multifocal GBM patients, in which independent lesions arise from the same progenitor and undergo parallel evolution, enables the study of the natural evolution of GBM while removing the effect of therapy on the emergence of heterogeneity. This enables the identification of critical events in the evolution of GBM and the unbiased study of subtype progression, diversity, and invasive potential. The tumor microenvironment of GBM undergoes significant changes throughout tumor progression. Recent studies have highlighted the switch from an abundance of resident microglia-derived macrophages in earlier stages to the prevalence of blood-derived macrophages in later stages of GBM. There is conclusive evidence that these alterations cannot be viewed in isolation and that the tumor microenvironment co-evolves with tumor cells during cancer progression. Together with an increasingly hypoxic environment, this culminates in highly immunosuppressive conditions, resulting in a feedback loop further reinforcing evolutionary changes in the tumor. A new study now provides a unique look at the natural evolution of GBM, identifies critical events in its development, and has the potential to help improve the diagnosis and therapy of this deadly disease.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Lymph nodes of the perimandibular area: from anatomical classification to pathological role in cancer of the oral cavity, oropharynx and skin 下颌骨周围淋巴结:从解剖分类到口腔、口咽和皮肤癌的病理作用

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.98

G. Tirelli, Francesco Uderzo, N. Gardenal, P. Boscolo-Rizzo, A. V. Marcuzzo

{"title":"Lymph nodes of the perimandibular area: from anatomical classification to pathological role in cancer of the oral cavity, oropharynx and skin","authors":"G. Tirelli, Francesco Uderzo, N. Gardenal, P. Boscolo-Rizzo, A. V. Marcuzzo","doi":"10.20517/2394-4722.2022.98","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.98","url":null,"abstract":"Lymph node status of the neck is the most important prognostic factor in head and neck cancer. Neck dissection, which consists of the systematic excision of the neck nodes, represents the gold standard of surgical treatment in clinically positive necks. In cases in which metastases to lymph nodes of the neck are not detectable, the decision to perform an elective neck dissection depends on the stage and the site of the primary tumor. This narrative review focuses on the anatomical description and oncological role of a group of lymph nodes of the neck that historically has not been well defined. Over the years, several authors have described the groups of lymph nodes that lie where the facial vein crosses the mandible, but to date, no unique definition or a clear view of their oncological role has been proposed. Recently, the term “perimarginal nodes” was coined to refer to this group of lymph nodes, and emphasis was placed on the risk of leaving them undissected during neck dissection. This paper aims to provide a surgical-anatomical classification of these lymph nodes and describe their oncological role on the basis of a review of the relevant literature.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67653022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radical skeletal metastatic site irradiation in high-risk neuroblastoma: systematic review and proposal for a randomised trial 高危神经母细胞瘤根治性骨骼转移部位照射:系统评价和随机试验建议

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.32

引用次数: 0

Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment. ssRNA(-)溶瘤病毒在宿主和肿瘤微环境中引发的免疫应答。

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-04-04 DOI: 10.20517/2394-4722.2022.92

Yonina Bykov, Gloria Dawodu, Aryana Javaheri, Adolfo Garcia-Sastre, Sara Cuadrado-Castano

{"title":"Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment.","authors":"Yonina Bykov, Gloria Dawodu, Aryana Javaheri, Adolfo Garcia-Sastre, Sara Cuadrado-Castano","doi":"10.20517/2394-4722.2022.92","DOIUrl":"10.20517/2394-4722.2022.92","url":null,"abstract":"Oncolytic viruses (OVs) are at the forefront of biologicals for cancer treatment. They represent a diverse landscape of naturally occurring viral strains and genetically modified viruses that, either as single agents or as part of combination therapies, are being evaluated in preclinical and clinical settings. As the field gains momentum, the research on OVs has been shifting efforts to expand our understanding of the complex interplay between the virus, the tumor and the immune system, with the aim of rationally designing more efficient therapeutic interventions. Nowadays, the potential of an OV platform is no longer defined exclusively by the targeted replication and cancer cell killing capacities of the virus, but by its contribution as an immunostimulator, triggering the transformation of the immunosuppressive tumor microenvironment (TME) into a place where innate and adaptive immunity players can efficiently engage and lead the development of tumor-specific long-term memory responses. Here we review the immune mechanisms and host responses induced by ssRNA(-) (negative-sense single-stranded RNA) viruses as OV platforms. We focus on two ssRNA(-) OV candidates: Newcastle disease virus (NDV), an avian paramyxovirus with one of the longest histories of utilization as an OV, and influenza A (IAV) virus, a well-characterized human pathogen with extraordinary immunostimulatory capacities that is steadily advancing as an OV candidate through the development of recombinant IAV attenuated platforms.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endocrine therapy in metastatic breast cancer-more than just CDK4/6 inhibitors 转移性乳腺癌的内分泌治疗-不仅仅是CDK4/6抑制剂

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 DOI: 10.20517/2394-4722.2022.94

引用次数: 0

Advanced breast cancer metastasized in the brain: treatment standards and innovations. 晚期乳腺癌脑转移：治疗标准与创新。

IF 1.9

Journal of Cancer Metastasis and Treatment Pub Date : 2023-01-01 Epub Date: 2023-06-14 DOI: 10.20517/2394-4722.2022.125

Elizabeth Klaas, Eric Sung, Esaan Azizi, Melanie Martinez, Arnav Barpujari, Jeffery Roberts, Brandon Lucke-Wold

引用次数: 0